Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

Pharmacogenetics of Leflunomide in the RA Management

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.

Who May Be Eligible (Plain English)

Who May Qualify: - At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10 - Pakistani individuals - between ages of 20-75 years - New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available Who Should NOT Join This Trial: - Patients not willing to participate/ consent not given - Patients below the age of 20 - Non- Pakistani origin - Taking another DMARD simultaneously - Compromised renal and hepatic functions - Cognitive impairment, neurological disease - Pregnant/ lactating patients - Patients having inflammatory bowel disease/ Irritable bowel syndrome - Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy- Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10 * Pakistani individuals * between ages of 20-75 years * New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available Exclusion Criteria: * Patients not willing to participate/ consent not given * Patients below the age of 20 * Non- Pakistani origin * Taking another DMARD simultaneously * Compromised renal and hepatic functions * Cognitive impairment, neurological disease * Pregnant/ lactating patients * Patients having inflammatory bowel disease/ Irritable bowel syndrome * Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-

Treatments Being Tested

DRUG

Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients

Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients

Locations (2)

Shifa International Hospital
Islamabad, Punjab Province, Pakistan
Fauji Foundation Hospital, Rawalpindi
Rawalpindi, Punjab Province, Pakistan